Budget Impact Analysis of Everolimus Plus Exemestane Versus Gemcitabine Plus Paclitaxel and Capecitabine Plus Docetaxel in Metastatic Breast Cancer Patients in Egypt
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2207
https://www.valueinhealthjournal.com/article/S1098-3015(14)04137-0/fulltext
Title :
Budget Impact Analysis of Everolimus Plus Exemestane Versus Gemcitabine Plus Paclitaxel and Capecitabine Plus Docetaxel in Metastatic Breast Cancer Patients in Egypt
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04137-0&doi=10.1016/j.jval.2014.08.2207
First page :
A622
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1665